GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGC Pharma Inc (FRA:IGS1) » Definitions » Operating Margin %

IGC Pharma (FRA:IGS1) Operating Margin % : -1,470.05% (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is IGC Pharma Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. IGC Pharma's Operating Income for the three months ended in Dec. 2023 was €-2.75 Mil. IGC Pharma's Revenue for the three months ended in Dec. 2023 was €0.19 Mil. Therefore, IGC Pharma's Operating Margin % for the quarter that ended in Dec. 2023 was -1,470.05%.

Warning Sign:

IGC Pharma Inc operating margin has been in a 5-year decline. The average rate of decline per year is -114.7%.

The historical rank and industry rank for IGC Pharma's Operating Margin % or its related term are showing as below:

FRA:IGS1' s Operating Margin % Range Over the Past 10 Years
Min: -3886.15   Med: -139.48   Max: -40.65
Current: -959.46


FRA:IGS1's Operating Margin % is ranked worse than
72.25% of 1027 companies
in the Biotechnology industry
Industry Median: -161.26 vs FRA:IGS1: -959.46

IGC Pharma's 5-Year Average Operating Margin % Growth Rate was -114.70% per year.

IGC Pharma's Operating Income for the three months ended in Dec. 2023 was €-2.75 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was €-10.83 Mil.


IGC Pharma Operating Margin % Historical Data

The historical data trend for IGC Pharma's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGC Pharma Operating Margin % Chart

IGC Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -90.75 -168.58 -971.88 -3,891.39 -1,269.92

IGC Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -686.90 -2,433.55 -385.55 -854.95 -1,470.05

Competitive Comparison of IGC Pharma's Operating Margin %

For the Biotechnology subindustry, IGC Pharma's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IGC Pharma's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGC Pharma's Operating Margin % distribution charts can be found below:

* The bar in red indicates where IGC Pharma's Operating Margin % falls into.



IGC Pharma Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

IGC Pharma's Operating Margin % for the fiscal year that ended in Mar. 2023 is calculated as

Operating Margin %=Operating Income (A: Mar. 2023 ) / Revenue (A: Mar. 2023 )
=-10.807 / 0.851
=-1,269.92 %

IGC Pharma's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-2.749 / 0.187
=-1,470.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IGC Pharma  (FRA:IGS1) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


IGC Pharma Operating Margin % Related Terms

Thank you for viewing the detailed overview of IGC Pharma's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


IGC Pharma (FRA:IGS1) Business Description

Traded in Other Exchanges
Address
10224 Falls Road, Potomac, MD, USA, 20854
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

IGC Pharma (FRA:IGS1) Headlines

No Headlines